A Nature Communications study reported results from a human trial testing deliberate colonization with a non-toxigenic Clostridioides difficile strain. Led by Hensen, Harmanus, Verbeek-Menken and colleagues, the work focused on safety and potential therapeutic benefit, challenging the long-standing convention of avoiding C. difficile colonization. The trial’s framing is notable: rather than treating infection after symptom onset, it explores using a safer colonization state to potentially prevent or mitigate harmful disease processes. The results are positioned as a step toward new infection-management strategies. For developers of microbiome and antimicrobial-adjacent products, the trial is a signal that controlled colonization approaches may become a more mainstream regulatory and clinical pathway—provided efficacy endpoints and durability data follow.